The latest price target for Neumora Therapeutics (NASDAQ:NMRA) was reported by Guggenheim on March 10, 2025. The analyst firm set a price target for $0.00 expecting NMRA to fall to within 12 months (a possible -100.00% downside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Neumora Therapeutics (NASDAQ:NMRA) was provided by Guggenheim, and Neumora Therapeutics downgraded their neutral rating.

There is no last upgrade for Neumora Therapeutics

The last downgrade for Neumora Therapeutics Inc happened on March 10, 2025 when Guggenheim changed their price target from N/A to N/A for Neumora Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neumora Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neumora Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.

While ratings are subjective and will change, the latest Neumora Therapeutics (NMRA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Neumora Therapeutics (NMRA) is trading at is $1.15, which is out of the analyst’s predicted range.